Eagle Genomics is the award winning software company helping life sciences companies bring new candidate medicines, therapies and products to patients and customers at vastly reduced cost and time.
Global R&D organisations have increased their spend on data integration initiatives to drive product innovation (drugs, companion diagnostics, personal care) or accurately predict phenotypic traits (disease susceptibility, patient stratification..
CAMBRIDGE, April 5, 2016 – Eagle Genomics announces the results of a novel insight on the International Cancer Genome Consortium (https://icgc.org/) data, with over 17,000 patient donors, resulting in a ranking of the most valuable constituent..
Molecular biomarkers are measurable properties that indicate biological state. These are fundamental to the development of today’s precision therapeutics and diagnostics. The current pace of development is phenomenal, but can we go still faster by..
Anthony Finbow has been working since September 2015 in advising Abel Ureta-Vidal (CEO) and the Board of Eagle Genomics in developing the business, in shaping the company’s product vision and in preparing the business for growth. Anthony replaces..
Eagle Genomics has secured a position in the IP100 League for 2016. The IP League was created by Metis Partners, and ranks UK companies based on their IP assets and value.